title: Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).
abstract: OBJECTIVE
  To compare the amount of intraoperative intraocular bleeding in patients with diabetes with macula-involving tractional retinal detachment (TRD) undergoing pars plana vitrectomy (PPV) with and without preoperative intravitreal bevacizumab (IVB) injection.
  
  
  METHODS
  An institutional study was carried out with consecutive patients with diabetic retinopathy and macula-involving TRD of recent (3 months) onset who were randomly assigned to PPV only (PPV group) or PPV combined with one IVB (1.5 mg/0.06 ml) injection 2 weeks prior to surgery (bevacizumab (BEV)/PPV group). All patients underwent 23-gauge PPV 3 weeks after baseline. The main outcome measure was erythrocyte count in the fluid retrieved from the vitrectomy cassette using a Neubauer counting chamber.
  
  
  RESULTS
  The study included 20 patients. The mean erythrocyte count was 14,865x10(3) (SD 19,332x10(3); median 4,500x10(3)) cells in the BEV/PPV group, and 176,240x10(3) (SD 108,375x10(3); median 166,600x10(3)) cells in the PPV group. The mean erythrocyte count was significantly lower in the BEV/PPV group than in the PPV group (p<0.0001). No major adverse events were identified.
  
  
  CONCLUSIONS
  Preoperative IVB injection was associated with reduced intraocular bleeding during 23-gauge PPV for diabetic macula-involving TRD. Further studies are needed to confirm our preliminary findings.
  
  
  BACKGROUND
  NCT00690768.
authors.affiliation: Department of Ophthalmology, School of Medicine of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil.
authors.forename: D
authors.initials: D
authors.lastname: da R Lucena
authors.forename: J A S
authors.initials: JA
authors.lastname: Ribeiro
authors.forename: R A
authors.initials: RA
authors.lastname: Costa
authors.forename: J C
authors.initials: JC
authors.lastname: Barbosa
authors.forename: I U
authors.initials: IU
authors.lastname: Scott
authors.forename: L L
authors.initials: LL
authors.lastname: de Figueiredo-Pontes
authors.forename: R
authors.initials: R
authors.lastname: Jorge
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000601:surgery*; D004906:Erythrocyte Count; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011229:Preanesthetic Medication; D011446:Prospective Studies; D012163:Retinal Detachment / Q000601:surgery*; D016896:Treatment Outcome; D014821:Vitrectomy / Q000009:adverse effects*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab